Gopal C. Kundu

Professor & Director R&D

Prof. Gopal C. Kundu has obtained his Ph.D. in Chemistry from Bose Institute, Kolkata, India (1989). He did his post-doctoral work at the Cleveland Clinic Foundation, University of Colorado, University of Wyoming, and the National Institutes of Health in USA in the area of cardiovascular research, inflammatory diseases and reproductive biology from 1989 to 1998. He joined as Scientist-D at National Centre for Cell Science (NCCS) in 1998 and then promoted to Scientist-E, -F and -G. His area of research at NCCS is tumor biology, cancer stem cells, tumor-stroma interaction, angiogenesis, cancer therapeutics biomarker development and nanomedicine. He has received several awards including Fellows Award for Research Excellence from NIH, USA; National Bioscience Award from DBT, New Delhi; Shanti Swarup Bhatnagar Prize from CSIR, New Delhi; International Award in Oncology from Greece; International Young Investigator Award from Mayo Clinic, USA and 7th National Grassroots Innovation Award from Rashtrapati Bhavan, India. He is Fellow of National Academy of Sciences and Indian Academy of Sciences. He has published about 96 papers including Nature Medicine, Science, PNAS (USA), Cancer Research, J. of Invest. Dermatology, J. of Biol. Chem, Trends in Cell Biol., Oncogene, Nanomedicine (London), Molecular Cancer, Nanoscale, Carcinogenesis, EMBO Reports, BMC Cancer etc and one US patent and two Indian Patents (Provisional). He serves as Editorial Board Member of Current Molecular Medicine, Current Chemical Biology, Molecular Medicine Reports, American Journal of Cancer Research and Associate Editor of Molecular Cancer and Journal of Cancer Metastasis and Treatment (JCMT). Prof. Kundu is an Adjunct Visiting Professor at Curtin University, Perth, Australia. Recently, Prof. Kundu served as Dean, Acting Director and Director (i/c) at National Centre for Cell Science, Pune from 2018-2019. Currently, Prof. Kundu is Director, R&D of KIIT Deemed to be University (KIIT DU), Institute of Eminence, Bhubaneswar. Prof. Kundu has taken additional charge as Professor of Biotechnology, School of Biotechnology (KIIT DU) and Professor of Medicine and Molecular Research, Kalinga Institute of Medical Science (KIMS), KIIT DU.

Profile Links

Email :
[email protected]
Website :
sites.google.com
Google Scholar :
https://scholar.google.com/citations?user=MIkkCeAAAAAJ&hl=en&oi=ao

Social Links

Educational Qualification
PhD (Chemistry)

Research Interests
  • Tumor Biology, Regulation of Gene Expression,
  • Targeted Drug Delivery, Angiogenesis
  • Cancer Stem Cells, Chemical Biology and Nanotechnology.
  • Tumor-immune cells interactions


Projects
  1. “Determination of biofilm pharmaco dynamics of newly formulated, nano-conjugated antibiotics to optimize treatment and dosing of chronic, antibiotic-resistant biofilm”, Funded by ICMR, Govt. of India, 2020-2023.
  2. ‘Multipronged approach for pre-clinical assessment of novel curcumin formulations as drugs for breast cancer therapy’’, Funded by DBT, Govt. of India, 2020-2023.
  3. ‘Multi-Omics analysis to decipher mechanism of hormone resistance in Breast cancer’’, Funded by DBT, Govt. of India, 2017-2022.


      4. Administrative Responsibility
      Director R&D, KIIT DU

      Awards & Honours
      1. Shanti Swarup Bhatnagar Prize in Biological Sciences, Council of Scientific and Industrial Research (CSIR), New Delhi, Govt. of India, 2004
      2. National Bioscience Award for Career Development, Dept. of Biotechnology (DBT), New Delhi, Govt. of India, 2003-2004
      3. International Young Investigator Award, 5th Mayo Clinic Angiogenesis Symposium, USA, 2012
      4. International Award for an outstanding achievement in Oncology, Greece, 2007 Platinum Jubilee Award Lecture, 99th Indian Science Congress Association, KIIT, Bhubaneswar, 2012
      5. Fellows Award for Research Excellence (FARE) from The National Institute of Health of Health (NIH), Bethesda, Maryland, USA, (1997)
      6. 7th National Grassroots Innovation Award-2013, Rashtrapati Bhavan, New Delhi, 2013
      7. Adjunct Visiting Professor, Curtin University, Perth, Australia (2017-2020)
      8. Selected NASI Senior Scientist Platinum Jubilee Fellowship, 2020
      9. Selected for Shri R.J. Kinariwala Research Award for lifetime Research Achievement in Cancer Research from Gujarat Cancer Research Institute, India, 2020
      10. The International Journal of Oncology, Greece published the lifetime work of Dr. Gopal C. Kundu as an Autobiography & Career Achievements as Editorial Academy Member of this Journal on its Cover Page in May, 2021


      Memberships
      1. Fellow of Indian National Science Academy (2023)
      2. Fellow of Royal Society of Chemistry (2023)
      3. Fellow of the National Academy of Sciences, India (2003)
      4. Fellow of the Indian Academy of Sciences (2006)
      5. Fellow of Maharashtra Academy of Science
      6. Editorial Board Member of Current Molecular Medicine, USA (2006)
      7. Member of American Society for Biochemistry and Molecular Biology, USA (2006)
      8. Editorial Board Member of Molecular Medicine Reports, Greece (2007)
      9. Senior Editorial Board Member of American Journal of Cancer Research (2011)
      10. Associate Editor, J. of Cancer Metastasis and Treatment (2015-)
      11. Editorial Board Member, World Academy of Sciences, Greece
      12. Editorial Board Member, Current Chemical Biology, USA
      13. Associate Editor, Molecular Cancer (IF: 37.3) (2015-till date)
      14. Member of Molecular Immunology Forum (MIF)
      15. Member of New York Academy of Sciences, USA (2000-2001)
      16. Member of Guha Research Conference (GRC) (2003)

Journals/Conferences :
1. Deepti Tomar, Amit S. Yadav, Dhiraj Kumar, Garima Bhadauriya, Kundu, GC: Non-coding RNAs as potential therapeutic targets in breast cancer. Biochim Biophys Acta Gene Regul Mech. 2019 Apr 29:194378. doi: 10.1016/j.bbagrm.2019.04.005. (IF: 6.3)
2. Sneha Mahalunkar, Amit Singh Yadav, Mahadeo Gorain, Vinay Pawar, Ranveig Braathen, Siegfried Weiss, Bjarne Bogen , Suresh W. Gosavi and Gopal C. Kundu. Functional Design of pH Responsive Folate Targeted Polymer Coated Gold Nanoparticles for Drug Delivery in Breast Cancer. Int J Nanomedicine. 2019 Oct 15; 14:8285-8302. doi: 10.2147/IJN.S215142. eCollection 2019. (IF:7.033)
3. Ashwini Wali, Mahadeo Gorain, Satish Inamdar, Gopal Kundu, and Manohar Badiger: In Vivo Wound Healing Performance of Halloysite Clay and Gentamicin-Incorporated Cellulose Ether-PVA Electrospun Nanofiber Mats. ACS Applied Bio Materials, (in press), 2019 (IF:0.746)
4. Romen Meitei Lourembam, Amit Singh Yadav, Gopal C. Kundu & Pranab Behari Mazumder: Curcuma zedoaria (christm.) roscoe inhibits proliferation of MDA-MB231 cells via caspase-cascade apoptosis. Oriental Pharmacy and Experimental Medicine. 19, 235–241(2019) (IF:2.0)
5. Ravindra Taware, Khushman Taunk, Totakura V. S. Kumar, Jorge A. M. Pereir, José S. Câmara, H. A. Nagarajaram, Gopal C. Kundu, Srikanth Rapole. Extracellular volatilomic alterations induced by hypoxia in breast cancer cells. Metabolomics. 2020 Jan 24;16(2):21. doi: 10.1007/s11306-020-1635-x. (IF: 4.747)
6. Amit S. Yadav, N Naga Venkata Radharani, Mahadeo Gorain, Anuradha Bulbule, Dattatrya Shetti, Gaurab Roy, Thejus Baby and Gopal C. Kundu: RGD functionalized chitosan nanoparticle mediated targeted delivery of raloxifene selectively suppresses angiogenesis and tumor growth in breast cancer: Nanoscale. 2020 May 21;12(19):10664-10684. doi: 10.1039/c9nr10673a. Epub 2020 May 6. (IF: 6.9)
7. Rajendra Prasad, Nishant K. Jain, Amit S. Yadav, Deepak S. Chauhan, Janhavi Devrukhkar, Mukesh K. Kumawat, Shweta Shinde, Mahadeo Gorain, Avnesh S. Thakor, Gopal C. Kundu, João Conde, Rohit Srivastava: Stepwise Assembly of Multimode Liposomal Nanotheranostic Agent for Targeted In Vivo Bioimaging and Near Infrared Light Mediated Cancer Therapy. Communications Biology, 2020Jun 5;3(1):284. doi:10.1038/s42003-020-1016-z. (IF:6.548)
8. Ipsita G Kundu, NNV Radharani, Amit S Yadav, Srinivas Patnaik, Gopal C Kundu: SARS-CoV-2: Origin, pathogenesis and Therapeutic Interventions. Coronaviruses, 2020. doi : 10.2174/2666796701999201209144207
9. Shalini Nath, Susmita Mondal, Ramesh Butti, Vinoth Prasanna
Gunasekaran, Gopal C. Kundu, Uttara Chatterjee, Aniket Halder, Chitra Mandal:. Desialylation of Sonic-Hedgehog by Neu2 Inhibits Its Association With Patched1 Reducing Stemness Properties in Pancreatic Cancer Sphere Cells. Cells, 2020 Jun 21;9(6):E1512. doi: 10.3390/cells9061512. (IF: 6.0)
10. Sonika Chibh, Bibhav Katoch, Avneet Kaur, Farheen Khanam, Amit Singh Yadav, Manish Singh, Gopal C. Kundu, Bhanu Prakash, Jiban Jyoti Panda: Continuous Flow Fabrication of Fmoc-Cysteine Based Nanobowl Infused Core-Shell Like Structures for pH Switchable on Demand Anti-Cancer Drug Delivery. Biomater Sci, 2021 Feb 9;9(3):942-959. doi: 10.1039/d0bm01386b.PMID: 33559658 (IF: 6.6)
11. Shreetama Bandyopadhayaya, Mikhail G. Akimov, Ranjeet Verma, Ankit Sharma, Divya Sharma, Gopal C. Kundu, Natalia M. Gretskaya, Vladimir V. Bezuglov, and Chandi C Mandal. N-arachidonoyl dopamine inhibits epithelial-mesenchymal transition of breast cancer cells through ERK signaling and decreasing the cellular cholesterol. Journal of Biochemical and Molecular Toxicology, 2020, DOI: 10.1002/jbt.22693 (IF: 3.568)
12. Mahalunkar S, Kundu GC, Gosavi SW. Folated curcumin-gold nanoformulations: A nanotherapeutic strategy for breast cancer therapy. Journal of Vacuum Science & Technology B (in press), 2020. (IF:1.4)

13. Prasad R, Jain NK, Yadav AS, Jadhav M, Radharani NNV, Gorain M, Kundu GC, Conde J, Srivastava R. Ultrahigh Penetration and Retention of Graphene Quantum Dot Mesoporous Silica Nanohybrids for Image Guided Tumor Regression. ACS Appl Bio Mater. 2021 Feb 15;4(2):1693-1703. doi: 10.1021/acsabm.0c01478. Epub 2021 Jan 8. PMID: 35014516, 2021 (IF: 0.746)
14. NNV Radharani, Ipsita G Kundu, Amit S Yadav and Gopal C Kundu. Oxidative Stress: A Key Regulator of Breast Cancer Progression and Drug Resistance. A Handbook of Oxidative Stress in Cancer (Springer Nature), 2021.
15. Ramesh Butti, VinothPrasanna Gunasekaran, Ramakrishna Nimma, Gautam Kundu, Deepti Tomar, Anuradha Bulbule, Dhiraj Kumar, Anupama Mane, Satyajith Gill, Tushar Patil, Georg F. Weber, Gopal C. Kundu: Tumor-derived Osteopontin Drives the Resident Fibroblast to Myofibroblast Differentiation through Twist1 to Promote Breast Cancer Progression. Oncogene, 2021 Mar;40 (11):2002-2017. doi: 10.1038/s41388-021-01663-2. Epub 2021 Feb 18.PMID: 33603163 (IF: 8.756)
16. Arpankumar Choksi, Apoorva Parulekar, Richa Pant, Vibhuti Kumar Shah, Ramakrishna Nimma, Priyanka Firmal, Smriti Singh, Gopal C. Kundu, Sanjeev Shukla and Samit Chattopadhyay: Nuclear matrix binding protein SMAR1 inhibits Warburg effect via regulation of PKM alternative splicing by HDAC6 mediated deacetylation of PTBP1 in breast cancer cells. Cancer Metab. 2021 Apr 16;9(1):16. doi: 10.1186/s40170-021-00252-x.PMID: 33863392 (IF: 5.469)
17. Butti Ramesh, Kumar TVS, Nimma Ramakrishna, Banerjee, Pinaki, Kundu, Ipsita G and Kundu Gopal C: Osteopontin Signaling in Shaping Tumor Microenvironment conductive to Malignant Progression. Adv Exp Med Biol. 2021;1329:419-441. doi: 10.1007/978-3-030-73119-9_20. (IF: 3.65)
18. Suvranil Ghosh, Naibedya Dutta, Pinaki Banerjee, Rahul L Gajbhiye, Hossainoor Rahaman Sareng, Prachi Kapse, Srabani Pal, Lyudmila Burdelya, Narayan C Mandal, Velyutham Ravichandiran, Ashish Bhattacharjee, Gopal C Kundu, Katerina Gurova, Andrei V Gudkov, and Mahadeb Pal: Ethyl acetate fraction of Bergenia ligulata sensitizes prostate cancer cells through monoamine oxidase A-mediated ROS generation and impairment of antioxidant defense response. Free Radical Biology and Medicine 2021 Jun 5;172:136-151. doi: 10.1016/j.freeradbiomed.2021.05.037. (IF: 8.1)
19. Georg F Weber, Gulimerouzi Fnu, Palak Agrawal, Gopal C Kundu: Structural Constraint of Osteopontin Facilitates Efficient Binding to CD44. Biomolecules 2021 May 30;11(6):813. doi: 10.3390/biom11060813. (IF: 6.064)
20. Ghuwalewala, Sangeeta ; Ghatak, Dishari; Das, Sumit; Das, Pijiush; Butti, Ramesh; Gorain, Mahadeo; Kundu, Gopal; Roychoudhury, Susanta. MiR-146a-dependent regulation of CD24/AKT/β-catenin axis drives cancer stem cell phenotype in oral squamous cell carcinoma. Frontiers in Oncology (in press), 2021. (IF: 6.24)
21. Ashwin Porwal , Gopal C Kundu , Gajanan Bhagwat, Ramesh Butti: Polyherbal formulation Anoac H suppresses the expression of RANTES and VEGF for the management of bleeding hemorrhoids and fistula. Molecular Med Reports. 2021 Oct;24(4):736. doi: 10.3892/mmr.2021.12376. Epub 2021 Aug 20. (IF: 3.423)
22. Ashwin Porwal, Gopal C. Kundu, Gajanan Bhagwat, Ramesh Butti: Herbal medicine AnoSpray suppresses proinflammatory cytokines COX 2 and RANTES in the management of hemorrhoids, acute anal fissures and perineal wounds. Expt. Ther. Med, 2021 (IF: 2.75)
23. A. Parulekar, A. Choksi, N. Taye, TVS Kumar, P. Firmal, Gopal C Kundu, Samit Chattopadhyay: SMAR1 Suppresses the Cancer Stem Cell Population via hTERT Repression in Colorectal Cancer Cells. Int J Biochem Cell Biol. 2021 Sep 20;141:106085. doi: 10.1016/j.biocel.2021.106085 (IF: 5.65)
24. Anivind Kaur Bindra, Sivaramapanicker Sreejith, Rajendra Prasad, Mahadeo Gorain, Rijil Thomas, Deblin Jana, Mui Hoon Nai, Gopal C. Kundu, Rohit Srivastava, Chwee Teck Lim, Yanli Zhao. A Plasmonic Supramolecular Nanohybrid as a Contrast Agent for Site-Selective Computed Tomography Imaging of Tumor. Advanced Functional Materials. First published: 02 December 2021, doi.org/10.1002/adfm.202110575 (IF 19.92)

25. NNV Radharani, Amit S. Yadav, Ramakrishna Nimma, TV Santosh Kumar, AnuradhaBulbule, Venkatesh Chanukuppa, Dhiraj Kumar,Srinivas Patnaik, Srikanth Rapaole, Gopal C. Kundu (2022): Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway. Cancer Cell Int. 2022; 22: 122. Published online 2022 Mar 17. doi: 10.1186/s12935-022-02527-9. (IF: 6.436)
26. Sumit Das, Shehnaz Bano, Prachi Kapse, and Gopal C. Kundu (2022): CRISPR Based Therapeutics: A New Paradigm in Cancer Precision Medicine. Molecular Cancer, 2022, 21 (85), doi.org/10.1186/s12943-022-01552-6. (IF: 37.3)
27. Chaitali Surve; Ananya Banerjee; Anupriya S; Rajasree Chakraborty; Dhiraj Kumar; Ramesh Butti; Mahadeo Gorain; Sabyasachi Parida; Gopal C Kundu; Supriya Shidhaye et al. Nanomedicine, 2022, DOI: 1 95600.2217/nnm-2021-0446 (IF: 6.096)

28. Ramesh Butti, Prachi Kapse, Garima Bhadhurya1, Amit S. Yadav, Suhail Ahmed, Rohan Chaubal, Pallavi Parab, Rasika Kadam, Amit Dutt, Sudeep Gupta, Gopal C Kundu: A Novel Patient-derived Orthotopic Xenograft (PDOX) for Hormone-resistant Breast Cancer. Oncology Reports, 2023 May; 49(5):99. doi: 10.3892/or.2023.8536. Epub 2023 Mar 31 (IF: 3.096)
29. Tandrima Mitra, Soumya S Mahapatra, Barnalee Mishra, Venketesh K Panda, Diksha Malhotra, Anusuya Roy Chowdhury, and Gopal C Kundu. Hypoxia and its Biological Implications for Cancer Therapy. Springer Nature, Book Chapter, 2023
30. Banerjee P, Kapse P, Siddique S, Kundu M, Choudhari J, Mohanty V, Malhotra D, Gosavi SW, Gacche RN, Kundu GC. Therapeutic implications of cancer stem cells in prostate cancer. Cancer Biol Med. 2023 Jun 5;20(6):401–20. doi: 10.20892/j.issn.2095-3941.2022.0714. PMID: 37282627; PMCID: PMC10291985.
31. Ramesh Butti and Gopal C Kundu. The molecular dialogue between the tumor cells and fibroblasts. Oncotarget, 2023 May 19;14:462-463. doi: 10.18632/oncotarget.28405
32. Murlidhar A Betallu , Shaileshkumar R Bhalara , Kailash B Sapnar , Vijay B Tadke, Keerti Meena , Ananya Srivastava , Gopal C Kundu , Mahadeo Gorain . Hybrid Inorganic Complexes as Cancer Therapeutic Agents: In-vitro Validation. Nanotheranostics. 2023 Mar 11;7(3):270-280. doi: 10.7150/ntno.81557. eCollection 2023.
33. Jasoda Choudhari , Ramakrishna Nimma , Snehal K Nimal , Santosh Kumar Totakura Venkata , Gopal C Kundu, Rajesh N Gacche. Prosopis juliflora (Sw.) DC phytochemicals induce apoptosis and inhibit cell proliferation signaling pathways, EMT, migration, invasion, angiogenesis and stem cell markers in melanoma cell lines. J Ethnopharmacol. 2023 Aug 10;312:116472. doi: 10.1016/j.jep.2023.116472. Epub 2023 Apr 14

34. N P Syamprasad, Siddhi Jain, Bishal Rajdev, Samir Ranjan Panda, Jagadeesh Kumar Gangasani , Veerabhadra Swamy Challa, Jayathirtha Rao Vaidya , Gopal C Kundu, V G M Naidu. AKR1B1 inhibition using NARI-29-an Epalrestat analogue-alleviates Doxorubicin-induced cardiotoxicity via modulating Calcium/CaMKII/MuRF-1 axis. Chem Biol Interact. 2023 Aug 25;381:110566. doi: 10.1016/j.cbi.2023.110566. Epub 2023 May 29.PMID: 37257577

35. Sponging of five tumour suppressor miRNAs by lncRNA-KCNQ1OT1 activates BMPR1A/BMPR1B-ACVR2A/ACVR2B signalling and promotes chemoresistance to hepatocellular carcinoma, Banerjee S----Gopal C Kundu, et al. Cell Death and Discovery, (in press), 2023